posted on 2024-05-31, 18:36authored byMohamed El Faydy, Loubna Lakhrissi, Naoufel Dahaieh, Khadija Ounine, Burak Tüzün, Nabila Chahboun, Ahmed Boshaala, Abeer AlObaid, Ismail Warad, Brahim Lakhrissi, Abdelkader Zarrouk
A new series of 1,2,3-triazole-8-quinolinol hybrids were
synthesized
in good yields using monosubstituted acetonitriles and 5-azidomethyl-8-quinolinol
as the starting reagents via a one-step protocol. The structures of
1,2,3-triazole-8-quinolinol hybrids were characterized by nuclear
magnetic resonance (1H and 13C NMR) spectroscopy
and elemental analysis. Antibacterial activity in vitro of all the
synthesized hybrids was investigated against Escherichia
coli (E. coli), Xanthomonas
fragariae (X. fragariae), Staphylococcus aureus (S. aureus), and Bacillus subtilis (B. subtilis) applying the methods of disk diffusion and
minimal inhibition concentration (MIC). Hybrid 7 exhibited
excellent antibacterial capacity, with an MIC value of 10 μg/mL
against S. aureus and 20 μg/mL
against B. subtilis, E. coli, and X. fragariae, which were comparable to those that of the standard antibiotic
nitroxoline. A structure–activity relationship (SAR) study
of 1,2,3-triazole-8-quinolinol hybrids showed that introducing electron-donating
substituents in the 1,2,3-triazole ring at the 4-position is important
for activity. Quantum chemical calculations have been undertaken to
employ the Gaussian software in the B3LYP, HF, and M062X basis sets
using 3-21g, 6-31g, and SDD levels to further explain linkages within
the antibacterial findings. Furthermore, molecular docking investigations
were also conducted to investigate the binding affinities as well
as the interactions of some hybrids with the target proteins. An absorption,
distribution, metabolism, excretion, and toxicity (ADME/T) investigation
was carried out to scrutinize the viability of employing the 1,2,3-triazole-8-quinolinol
hybrids as medicines.